FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362458501> ?p ?o ?g. }

• W4362458501 endingPage "263" @default.
• W4362458501 startingPage "253" @default.
• W4362458501 abstract "The combination of cyclin-dependent kinase 4/6 inhibitors and endocrine therapy is a standard treatment for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC); however, their toxicities and financial burden are major issues, especially for prolonged treatment. We investigated fulvestrant plus palbociclib in patients with HR-positive MBC resistant to fulvestrant monotherapy.Patients who initially received fulvestrant as their first- or second-line endocrine therapy were assigned to group A. Patients with disease progression during fulvestrant monotherapy who subsequently received fulvestrant plus palbociclib were assigned to group B. The primary endpoint was progression-free survival (PFS1) in group B. We set the threshold median PFS of 5 months (null hypothesis).Between January 2018 and February 2020 we enrolled 167 patients in group A (January 2018-February 2020) from 55 institutions, of whom 72 subsequently received fulvestrant plus palbociclib and were enrolled in group B. The median follow-up was 23.8 and 8.9 months in groups A and B, respectively. The median PFS in group B (combination therapy) was 9.4 (90% confidence interval [CI]: 6.9-11.2) months (p < 0.001). This was 25.7 (90% CI: 21.2-30.3) months in group A (fulvestrant monotherapy). The TTF in group B was 7.2 (90% CI: 5.5-10.4) months. In the post-hoc analysis, the median PFS1 in group B among patients with longer-duration fulvestrant monotherapy (> 1 year) was longer than that of patients with shorter-duration monotherapy (≤ 1 year) (11.3 vs. 7.6 months). No new toxicities were observed.Our findings suggest that palbociclib plus fulvestrant after disease progression despite fulvestrant monotherapy is potentially safe and effective in patients with HR-positive/HER2-negative advanced MBC." @default.
• W4362458501 created "2023-04-05" @default.
• W4362458501 creator A5001674051 @default.
• W4362458501 creator A5011309808 @default.
• W4362458501 creator A5015450747 @default.
• W4362458501 creator A5020236389 @default.
• W4362458501 creator A5024725726 @default.
• W4362458501 creator A5031973637 @default.
• W4362458501 creator A5036168618 @default.
• W4362458501 creator A5038169777 @default.
• W4362458501 creator A5046753596 @default.
• W4362458501 creator A5052487318 @default.
• W4362458501 creator A5066441780 @default.
• W4362458501 creator A5067189124 @default.
• W4362458501 creator A5067693447 @default.
• W4362458501 creator A5085154668 @default.
• W4362458501 creator A5087154078 @default.
• W4362458501 creator A5088448746 @default.
• W4362458501 creator A5088924059 @default.
• W4362458501 date "2023-03-31" @default.
• W4362458501 modified "2023-10-07" @default.
• W4362458501 title "Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)" @default.
• W4362458501 cites W1985389450 @default.
• W4362458501 cites W2142334766 @default.
• W4362458501 cites W2148345265 @default.
• W4362458501 cites W2154626333 @default.
• W4362458501 cites W2290950904 @default.
• W4362458501 cites W2404884142 @default.
• W4362458501 cites W2552099557 @default.
• W4362458501 cites W2558360748 @default.
• W4362458501 cites W2560635244 @default.
• W4362458501 cites W2611480635 @default.
• W4362458501 cites W2620993107 @default.
• W4362458501 cites W2805575723 @default.
• W4362458501 cites W2807927321 @default.
• W4362458501 cites W2896846857 @default.
• W4362458501 cites W2901270440 @default.
• W4362458501 cites W3203674089 @default.
• W4362458501 cites W4239051461 @default.
• W4362458501 cites W4280490473 @default.
• W4362458501 cites W4297984276 @default.
• W4362458501 doi "https://doi.org/10.1007/s10549-023-06911-5" @default.
• W4362458501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37000345" @default.
• W4362458501 hasPublicationYear "2023" @default.
• W4362458501 type Work @default.
• W4362458501 citedByCount "1" @default.
• W4362458501 countsByYear W43624585012023 @default.
• W4362458501 crossrefType "journal-article" @default.
• W4362458501 hasAuthorship W4362458501A5001674051 @default.
• W4362458501 hasAuthorship W4362458501A5011309808 @default.
• W4362458501 hasAuthorship W4362458501A5015450747 @default.
• W4362458501 hasAuthorship W4362458501A5020236389 @default.
• W4362458501 hasAuthorship W4362458501A5024725726 @default.
• W4362458501 hasAuthorship W4362458501A5031973637 @default.
• W4362458501 hasAuthorship W4362458501A5036168618 @default.
• W4362458501 hasAuthorship W4362458501A5038169777 @default.
• W4362458501 hasAuthorship W4362458501A5046753596 @default.
• W4362458501 hasAuthorship W4362458501A5052487318 @default.
• W4362458501 hasAuthorship W4362458501A5066441780 @default.
• W4362458501 hasAuthorship W4362458501A5067189124 @default.
• W4362458501 hasAuthorship W4362458501A5067693447 @default.
• W4362458501 hasAuthorship W4362458501A5085154668 @default.
• W4362458501 hasAuthorship W4362458501A5087154078 @default.
• W4362458501 hasAuthorship W4362458501A5088448746 @default.
• W4362458501 hasAuthorship W4362458501A5088924059 @default.
• W4362458501 hasBestOaLocation W43624585011 @default.
• W4362458501 hasConcept C121608353 @default.
• W4362458501 hasConcept C126322002 @default.
• W4362458501 hasConcept C143998085 @default.
• W4362458501 hasConcept C2775930923 @default.
• W4362458501 hasConcept C2776999253 @default.
• W4362458501 hasConcept C2779744173 @default.
• W4362458501 hasConcept C2780482068 @default.
• W4362458501 hasConcept C530470458 @default.
• W4362458501 hasConcept C71924100 @default.
• W4362458501 hasConcept C84606932 @default.
• W4362458501 hasConceptScore W4362458501C121608353 @default.
• W4362458501 hasConceptScore W4362458501C126322002 @default.
• W4362458501 hasConceptScore W4362458501C143998085 @default.
• W4362458501 hasConceptScore W4362458501C2775930923 @default.
• W4362458501 hasConceptScore W4362458501C2776999253 @default.
• W4362458501 hasConceptScore W4362458501C2779744173 @default.
• W4362458501 hasConceptScore W4362458501C2780482068 @default.
• W4362458501 hasConceptScore W4362458501C530470458 @default.
• W4362458501 hasConceptScore W4362458501C71924100 @default.
• W4362458501 hasConceptScore W4362458501C84606932 @default.
• W4362458501 hasFunder F4320307770 @default.
• W4362458501 hasIssue "2" @default.
• W4362458501 hasLocation W43624585011 @default.
• W4362458501 hasLocation W43624585012 @default.
• W4362458501 hasLocation W43624585013 @default.
• W4362458501 hasOpenAccess W4362458501 @default.
• W4362458501 hasPrimaryLocation W43624585011 @default.
• W4362458501 hasRelatedWork W2292433415 @default.
• W4362458501 hasRelatedWork W2613342381 @default.
• W4362458501 hasRelatedWork W2751810360 @default.
• W4362458501 hasRelatedWork W2754339892 @default.
• W4362458501 hasRelatedWork W2965020061 @default.

• next